Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir monotherapy in virologically suppressed HIV patients (MONODO)
NCT02572947Phase 2Completed
- Sponsor
- Alexandra Calmy
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Alexandra Calmy. Primary endpoint: Number of patients without virological failure at 24 weeks. Started Jun 2016; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02572947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572947.